KAKeiichi Akahoshi

Keiichi Akahoshi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keiichi Akahoshi has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Broad Genomic Profiling Reveals Cancer Type–Specific Molecular Alterations with Potential Prognostic and Translational Relevance in Hepatobiliary and Pancreatic Cancers

    by Shotaro Gan, Keiichi Akahoshi, Shuichi Watanabe, Hiroki Ueda, Toshihiro Tanaka, Sadakatsu Ikeda, Daisuke Ban

    Background Comprehensive genomic profiling (CGP) is increasingly used in precision oncology, but actionable alterations remain limited in hepatobiliary and pancreatic (HBP) cancers. We investigated whether broader genomic coverage provides additional molecular information and potential prognostic or translational relevance. Methods This retrospective single-center study included 309 surgically resected HBP cancers: hepatocellular carcinoma (HCC), bile duct cancer (BDC), pancreatic ductal adenocarcinoma (PDAC), and neuroendocrine neoplasms (NENs). Tumors underwent CGP using ACT Onco+®, covering 440 cancer-related genes and 31 fusion genes. Panel content was compared with FoundationOne® CDx and NCC Oncopanel®, and exploratory survival analyses were performed for frequently altered ACT-only genes. Results A total of 4,476 genomic alterations were identified, with a median of 13 per patient. Cancer type-specific profiles included frequent CTNNB1 alterations in HCC, TP53 in BDC, KRAS in PDAC, and MEN1 in NENs. Of the 440 genes, 174 were ACT-only. Five of the ten most frequently altered genes—MUC16, SYNE1, USH2A, FAT1, and LRP1B—were ACT-only and were observed across multiple HBP cancer types. FAT1 alterations were associated with shorter recurrence-free survival in HCC (P = 0.012), whereas no postoperative recurrence occurred among patients with USH2A-altered NENs (P = 0.044). Several ACT-only genes or related pathways were linked to ongoing therapeutic development, although their predictive relevance remains unestablished. Conclusions Broader genomic profiling identified frequent alterations not covered by commonly used CGP panels, including ACT-only genes showing cancer type-specific associations with postoperative recurrence. Expanded gene coverage may provide additional molecular information beyond established actionable alterations in HBP cancers.

  • Expert Survey on Chyle Leakage After Pancreaticoduodenectomy: The Precision Anatomy for Minimally Invasive Hepato‐Biliary‐Pancreatic Surgery ( PAM ‐ HBP Surgery) Project 2024

    by Hitoe Nishino, Atsushi Oba, Keiichi Akahoshi, Taiga Wakabayashi, Chang Moo Kang, Shin‐E. Wang, Deeksha Kapoor, Benedict Kinny‐Köster, Ramiro Fernández‐Placencia, Yasuko Matsuo, et al.

    Background/Purpose: Chyle leakage (CL) after pancreaticoduodenectomy (PD) remains an underestimated complication with a consistent incidence. This expert survey analyzed its occurrence from anatomical and surgical perspectives. Methods: A structured survey was distributed to 57 surgeons from 10 countries, with extensive experience in open and minimally‐invasive pancreatectomy. Results: Most experts reported CL incidence as: open ≥ laparoscopic, open > robotic, and laparoscopic = robotic. They identified three major anatomical pitfalls: (i) the transverse mesocolon on the ventral side of the superior mesenteric artery and vein (SMA/SMV), (ii) the meso‐jejunum on the dorsal side of the SMA/SMV, and (iii) the fusion fascia of Treitz on the ventral side of the inferior vena cava (IVC). For lymphatic dissection and control, energy devices were favored across all approaches, whereas ligation was more common in open PD and clipping more frequent in robotic PD. Opinions on the optimal dissection plane at the fusion fascia of Treitz varied: along the pancreatic surface (21%), within the fascia (31%), or exposing the IVC (38%). Conclusions: Expert opinions suggest that the incidence of CL after PD does not differ significantly between open and minimally invasive approaches. Consensus emerged regarding common anatomical pitfalls, which may inform strategies for prevention.

  • Global Survey of Technical Preferences for Robotic Versus Laparoscopic Segmentectomy of Liver Segments 7 and 8: A 2024 PAM ‐ HBP Surgery Project

    by Keiichi Akahoshi, Taiga Wakabayashi, Hitoe Nishino, Atsushi Oba, Paolo Magistri, Kenichiro Araki, Kwangpyo Hong, Ruben Ciria, Iswanto Sucandy, Catherine Teh, et al.

    Background: Segmentectomy of liver segments 7 and 8 (S7/8) is technically challenging due to their posterosuperior location and proximity to major hepatic veins. With the increasing adoption of robotic surgery, current practices for S7/8 resection across different surgical modalities remain unclear. Methods: An international web‐based survey was conducted in 2024 among expert hepatobiliary surgeons. The 18‐item questionnaire addressed institutional policies, technical preferences, and procedural strategies for laparoscopic and robotic S7/8 segmentectomy. Results: A total of 67 surgeons from 11 countries responded. Among them, 51% had performed over 20 laparoscopic S7/8 resections, whereas 57% had no experience with the robotic approach. Robotic S7/8 segmentectomy accounted for fewer than 20% of cases at most institutions. The Glissonean approach from the hilum and the Maryland bipolar dissector were more frequently used in robotic procedures. The cranio‐dorsal approach to the right hepatic vein was less common in robotic surgery, while the cranio‐ventral approach to the middle hepatic vein was common to both modalities. Conclusions: Robotic S7/8 segmentectomy remains in the early stages of adoption despite ergonomic and technical advantages. This international survey highlights distinct technical differences between laparoscopic and robotic approaches, emphasizing the need for targeted training and standardized device integration.

  • Open Access

    H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression

    by Masahiro Yamane, Yoshimitsu Akiyama, Shu Shimada, Shuichi Watanabe, Megumi Hatano, Shu Tsukihara, Suguru Miyazawa, Hanako Tamura, Atsushi Nara, Keita Kodera, et al.


  • Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time‐Dependent Cox Regression Model

    by Denys Tsybulskyi, Daisuke Hashimoto, Kimitaka Tanaka, Kenta Murotani, Masataka Taguri, So Yamaki, Shoki Sato, Atsushi Oba, Yosuke Inoue, Shimpei Otsuka, et al.

    Background: Recently, surgical resection has been attempted for postoperative recurrence of pancreatic ductal adenocarcinoma ( PDAC ). This multicenter study aimed to investigate whether resection of any recurrent lesion contributes to the survival of patients with PDAC. Methods: This retrospective study of the Hepato‐Pancreato‐Biliary Scientific Network for Clinical Oncology Research Working Cohort involved patients with resectable/borderline resectable PDAC who underwent surgery between 2013 and 2019 and who subsequently developed recurrence after resection of the primary PDAC . A time‐dependent Cox regression model adjusted for various patient background and clinicopathological factors was used. Results: The study cohort comprised 1527 patients; 96 underwent resection for recurrence, including hepatectomy in 12 patients, pneumonectomy in 40, and pancreatectomy in 42. Overall survival after the initial treatment of primary PDAC was significantly better in patients who underwent resection compared with those who did not (75.0 vs. 25.8 months). The time‐dependent Cox regression model indicated that pneumonectomy for lung metastasis ( HR = 0.12) and pancreatectomy for recurrence in the pancreatic remnant ( HR = 0.20) significantly affected overall survival, whereas hepatectomy for liver metastasis was not ( HR = 0.46). Conclusion: Resection for postoperative recurrence of PDAC may offer survival benefits for selected patients, especially for lung metastasis and residual pancreatic recurrence. Trial Registration: https://ClinicalTrials.gov identifier: UMIN000049664


  • Open Access

    Jejunal Loop-Preserving and Mesentery-Sparing Reconstruction after Pancreaticoduodenectomy in a Patient with Prior Total Gastrectomy

    by Rena Mototani, Keiichi Akahoshi, Takaki Furuyama, Daisuke Asano, Yoshiya Ishikawa, Hiroki Ueda, Eriko Katsuta, Daisuke Ban

    INTRODUCTION: Pancreaticoduodenectomy (PD) after a total gastrectomy is technically challenging because the proximal jejunum has already been utilized for an esophagojejunostomy. Consequently, reconstruction after PD requires the use of a more distal jejunal segment, and the optimal reconstruction strategy remains controversial. We report a case of a jejunal loop-preserving and mesentery-sparing reconstruction after PD in a patient with a prior total gastrectomy.CASE PRESENTATION: A 70-year-old man with a history of Roux-en-Y total gastrectomy for gastric cancer presented with obstructive jaundice. Imaging studies demonstrated a periampullary tumor with suspected regional lymph node metastasis, and ampullary carcinoma was diagnosed. A PD was performed through an upper midline laparotomy. Following the resection of the pancreatic head and proximal jejunum, reconstruction was achieved using the pre-existing Roux limb without additional mesenteric division. Pancreaticojejunostomy and hepaticojejunostomy were performed using a distal jejunal segment, followed by a side-to-side jejunojejunostomy that preserved jejunal continuity and mesenteric integrity. The operative time was 459 minutes, and blood loss was 603 mL. The postoperative course was uneventful, and the patient was discharged on POD 21. Histopathological examination confirmed adenocarcinoma of the ampulla of Vater (pT3bN1M0, Stage IIIA) with negative surgical margins.CONCLUSIONS: This jejunal loop-preserving and mesentery-sparing reconstruction avoided additional jejunal transection and mesenteric dissection while maintaining the continuity of the jejunal loop. The technique may represent a simple and anatomically reasonable alternative to conventional double Roux-en-Y reconstruction in selected patients undergoing PD after a total gastrectomy.

  • Open Access

    Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies

    by Keiichi Akahoshi, Shun Kaneko, Shinji Tanaka, Minoru Tanabe, Daisuke Ban

    The therapeutic landscape of hepatocellular carcinoma (HCC) has been transformed by recent advancements in systemic therapies, particularly with the introduction of immune checkpoint inhibitors, expanding treatment options beyond conventional locoregional approaches. This review provides an overview of evidence accumulated from recent Phase III trials of first‐line regimens and key second‐line agents and examines how these advances enable multidisciplinary treatment strategies and timely transition to curative local treatments. We highlight prospective and retrospective data on systemic therapy administered in combination with or in sequence with locoregional treatment modalities, including TACE‐based combinations and “conversion” concepts leading to resection. A central focus is the oncological resectability criteria proposed by the Japan Liver Cancer Association and the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery, which provide an objective framework to assess surgical indications under contemporary systemic therapy. Validation studies have consistently demonstrated robust prognostic stratification across resectable (R), borderline resectable 1 (BR1), and borderline resectable 2 (BR2) categories. Evidence for application of the oncological resectability criteria in treatment decision‐making is still insufficient. Thus, future prospective studies and real‐world registries aligned with the resectability framework are essential for defining the optimal timing, sequencing, and candidacy for surgery to ultimately enable provision of individualized, evidence‐based care for patients with advanced HCC.


  • Open Access

    Comparative analysis of streptozocin-based regimen and capecitabine–temozolomide therapy in advanced pancreatic neuroendocrine neoplasms: influence of tumor grade and Ki-67 index

    by Yohei Tabe, Hiroaki Ono, Satoshi Matsui, Daisuke Asano, Yoshiya Ishikawa, Hiroki Ueda, Keiichi Akahoshi, Eriko Katsuta, Daisuke Ban

    Background: Systemic therapy is a standard treatment option for pancreatic neuroendocrine neoplasms (Pan-NENs) with unresectable or metastatic disease. Streptozocin (STZ)-based chemotherapy is considered a standard treatment option for tumors with a high Ki-67 index or for cases refractory to molecular targeted agents. More recently, the combination of capecitabine and temozolomide (CAPTEM) therapy has emerged as a new treatment option. Objectives: This study aimed to compare the efficacy, safety, and clinical outcomes between the STZ-based regimen and CAPTEM therapy in patients with unresectable or metastatic Pan-NENs. Design: This was a single-center retrospective study of histologically confirmed Pan-neuroendocrine tumor (NET) patients treated with either STZ-based regimens or CAPTEM between November 2015 and June 2024. Methods: We compared efficacy, safety, and clinical outcomes between the two regimens. Tumor responses were assessed using Response Evaluation Criteria in Solid Tumors version 1.1, and adverse events were graded according to Common Terminology Criteria for Adverse Events version 5.0. The study was conducted in compliance with the STROBE guidelines. Results: Of the 371 patients diagnosed with Pan-NENs, 47 received STZ-based regimen and 21 received CAPTEM therapy. In the NET-G1/G2 patients, the STZ group showed a significantly higher tumor shrinkage rate compared to CAPTEM therapy. Although no significant differences were observed in progression-free survival (PFS) or overall survival between the two groups, subgroup analysis showed that the median PFS in the STZ group was significantly longer than that in the CAPTEM group in NET G1/G2 patients. Renal dysfunction was the main adverse event in the STZ regimen group, while gastrointestinal symptoms were common in the CAPTEM therapy group; however, both were manageable. Conclusion: Both STZ-based regimen and CAPTEM therapy are safe and effective treatment options for advanced Pan-NENs. STZ-based regimen was more beneficial in NET-G1/G2 patients, suggesting Ki-67 index and tumor grade may serve as indicators for treatment selection. Further prospective studies are warranted to validate these findings.


  • Open Access

    Supplementary Figure S10 from PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer

    by Kentaro Umemura, Yoshimitsu Akiyama, Shu Shimada, Megumi Hatano, Ayumi Kono, Koya Yasukawa, Atsushi Kamachi, Yosuke Igarashi, Shu Tsukihara, Yoshiaki Tanji, et al.

    Transcriptome-based correlation of PAD2 and PRUNE1 and prognostic significance of PRUNE1 and CD206 in PDAC

  • Open Access

    Supplementary Figure S3 from PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer

    by Kentaro Umemura, Yoshimitsu Akiyama, Shu Shimada, Megumi Hatano, Ayumi Kono, Koya Yasukawa, Atsushi Kamachi, Yosuke Igarashi, Shu Tsukihara, Yoshiaki Tanji, et al.

    Expression of PAD family in normal pancreatic ductal cells and PDAC cell lines